Building a Path Forward with FENIB

Receiving a diagnosis of Familial Encephalopathy with Neuroserpin Inclusion Bodies (FENIB) can feel overwhelming, especially because the name itself is complex and the condition is so rare. FENIB is an ultra-rare, inherited neurodegenerative disorder that primarily affects the brain ^[1][2]. Because it is a “conformational proteinopathy,” it belongs to the broad category of protein-misfolding diseases, though it is clinically and genetically distinct from other disorders in this category, such as Alzheimer’s or Parkinson’s ^[2].

Understanding the Rarity

If your local doctors have limited direct experience with FENIB, it is because the condition is exceptionally rare. To date, published cases remain very few, with only about 13 published cases in recent reviews of the medical literature ^[3]. This means that many clinicians will have limited direct experience. Your family is likely entering a journey where you and your care team will be learning together. This lack of data can be frustrating and isolating, but it also highlights why seeking out specialists at major academic research centers or asking for an expert consultation is often useful to find the most current insights ^[3]. Local clinicians can still provide excellent coordinated care.

The Genetic Cause

The condition is caused by a mutation in the SERPINI1 gene ^[1]. This gene provides instructions for making a protein called neuroserpin, which is normally found in the connections between brain cells. In people with FENIB, the mutation causes the neuroserpin protein to become unstable and sticky. Instead of doing its job, the protein clumps together to form “polymers”—long chains that get stuck inside the brain cells ^[2][4].

These clumps are called inclusion bodies (historically known as Collins bodies) ^[3]. As these clusters build up over time, they damage the neurons, leading to the symptoms of the disease ^[5][6]. FENIB is an autosomal dominant condition, meaning only one copy of the mutated gene is needed to cause the disease ^[1]. While it can be inherited from a parent, some cases occur “de novo,” meaning the mutation happened for the first time in the patient and was not passed down from a parent ^[6].

Core Symptoms and Presentation

While the timing of symptoms varies, the disease is reported to feature a combination of decline.

• Progressive Myoclonic Epilepsy: This is one of the most defining features of FENIB ^[3]. It involves myoclonus (sudden, involuntary muscle jerks) and various types of seizures ^[3]. In many cases, these seizures can be difficult to control, as they often do not respond well to standard antiseizure medications ^[3].
• Progressive Cognitive Decline: This refers to a steady loss of memory, thinking skills, and the ability to perform daily tasks ^[3]. In some cases, behavioral changes like inattention or a loss of social filters may appear even before the seizures start ^[6].
• Motor Changes: Many patients develop dyskinesia (uncontrolled, involuntary body movements) or coordination issues as the disease advances ^[3].

The speed at which these symptoms progress often depends on the specific mutation in the SERPINI1 gene. Some mutations cause the protein to clump very quickly, leading to symptoms in childhood or adolescence, while others may not show signs until early or middle adulthood ^[2][3].

Management and Care

Currently, there is no cure for FENIB, and treatment focuses on managing symptoms and maintaining quality of life ^[7]. Because the condition is so rare, there is no single “standard” treatment plan. Care includes supportive (palliative) care, meaning it focuses on providing relief from symptoms like seizures and muscle jerks alongside active treatment while supporting the family ^[7].

• Seizure Management: Doctors may try several different antiseizure medications, though they may warn you that success can be limited ^[3].
• Multidisciplinary Support: As the disease progresses, families often need a team that includes neurologists, speech therapists (to help with swallowing issues), and physical therapists ^[8][9].
• Experimental Research: While there are no currently recruiting human clinical trials for FENIB, researchers are studying “gene editing” and “small molecules” in labs to see if they can stop the protein from clumping ^[10][11]. These are still in very early stages, have no established clinical benefit, and are not yet available for patients.

The emotional weight of a FENIB diagnosis is heavy. It is a progressive disease with a difficult prognosis; in highly selected, older documented cases, the median age of death was reported at 33 years, though this is not a validated survival estimate for any individual and varies by mutation ^[3]. Facing a disease that has no established roadmap requires immense strength. Connecting with rare-disease organizations and palliative care teams early on can help you navigate the physical and emotional challenges ahead.